Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash from Investing Activities: 2019-2024

Historic Cash from Investing Activities for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to -$1.9 million.

  • Keros Therapeutics' Cash from Investing Activities rose 65.80% to -$132,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year increase of 21.85%. This contributed to the annual value of -$1.9 million for FY2024, which is 21.63% up from last year.
  • According to the latest figures from FY2024, Keros Therapeutics' Cash from Investing Activities is -$1.9 million, which was up 21.63% from -$2.5 million recorded in FY2023.
  • Over the past 5 years, Keros Therapeutics' Cash from Investing Activities peaked at -$294,000 during FY2020, and registered a low of -$2.5 million during FY2023.
  • Its 3-year average for Cash from Investing Activities is -$1.9 million, with a median of -$1.9 million in 2024.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first slumped by 248.30% in 2021, then grew by 21.63% in 2024.
  • Over the past 5 years, Keros Therapeutics' Cash from Investing Activities (Yearly) stood at -$294,000 in 2020, then crashed by 248.30% to -$1.0 million in 2021, then fell by 21.19% to -$1.2 million in 2022, then tumbled by 98.55% to -$2.5 million in 2023, then increased by 21.63% to -$1.9 million in 2024.